BeiGene Ltd. (ONC)
220.04
-3.46 (-1.55%)
At close: Feb 10, 2025, 3:59 PM
219.67
-0.17%
After-hours Feb 10, 2025, 04:01 PM EST
undefined% (undefined)
| Bid | 216 |
| Market Cap | 25.23B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -8.18 |
| PE Ratio (ttm) | -26.9 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 226 |
| Volume | 266,080 |
| Avg. Volume (20D) | 370,146 |
| Open | 225.11 |
| Previous Close | 223.50 |
| Day's Range | 219.15 - 226.07 |
| 52-Week Range | 126.97 - 248.16 |
| Beta | undefined |
About ONC
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a sel...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 2, 2016
Employees 10,600
Stock Exchange NASDAQ
Ticker Symbol ONC
Website https://www.beigene.com
Next Earnings Release
BeiGene Ltd. is scheduled to release its earnings on Feb 24, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+0.02%
ImmunityBio shares are trading higher after the co...
Unlock content with
Pro Subscription
